J-147 Powder Complete Buying Guide and Review(2)

www.aasraw.com

J-147 Powder Complete Buying Guide and Review(2)

2. SARMS J-147 powder Usage J147 Powder cas: 1146963-51-0 was originally developed in 2011, and AASraw researchers conducted some studies demonstrating that it can reverse memory decline and slow or reverse Alzheimer’s disease in mice. AASraw researchers use a variety of methods to understand how J147 powder works. They finally determined that the target of J147 powder is a mitochondrial protein called ATP synthase, especially ATP5A, a subunit of this protein. ATP synthase is involved in the mitochondrial production of ATP by cells for energy. By reducing the activity of ATP synthase, they are able to protect neuronal cells from multiple types of toxicity associated with brain aging. One reason for this neuroprotective effect is thought to be the role of excitotoxicity in neuronal cell injury. J147 Powder binds to proteins found in mitochondria, the drug plays a significant role. This is a powerful force for cells, which in turn causes cells to function in a younger way.

1

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

In a new study, the AASraw team discovered that J147 powder cas: 1146963-51-0 binds to a protein called ATP synthase, which is responsible for producing a common cellular “energy currency�, ATP. This protein is known to control the aging of worms and flies. The researchers found that by combining with drugs, the drug can prevent age-related brain damage. The role of ATP synthase in inhibiting neuroprotection against excitotoxicity was demonstrated. The second study showed that a mouse model that expresses the human form of mutant ATPase inhibitor 1 (hIF1) (resulting in sustained inhibition of ATP synthase) is more amenable to neuronal death following excitotoxic injury. This data is consistent with this new J147 study in which increased IF1 in mice reduced the activity of ATP synthase (especially ATP5A) and was neuroprotective.

The data presented here indicate that J147 powder cas: 1146963-51-0 has the ability to rescue cognitive deficits upon late administration of the disease. The ability of J147 powder to improve memory function in aged AD mice is related to its induction of the neurotrophic factors NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor) and several BDNF-responsive proteins important for learning and memory. A comparison of J147 powder and scopolamine in scopolamine model shows that although both compounds are comparable in saving short-term memory, J147 powder is superior in rescuing spatial memory, and the combination of the two is most effective in contextual memory and memory.

2

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com

www.aasraw.com

In addition, AASraw studied other molecules affected by J147 powder cas: 1146963-51-0 in addition to ATP to find new drug targets. At the same time, this drug has passed the animal toxicology test and will enter the first phase of the human clinical trial soon, waiting for further funding

3. SARMS J 147 Dosage to Be Taken The Recommend J147 Powder Dosage: 20-30mg for neurological protection, neuroregenerative, anti-neurodegenerative, antidepressant, Alzheimer disease. 5-15mg for cognitive enhancement. Applications within sublingual hydroalcoholic-glycerin based tinctures may be significantly superior.

In vitro: sarms J 147 powder was used at 1 µM in vitro and in cellular assays.

In vivo: sarms J 147 powder was orally dosed to mice at 1-5 mg/kg once per day. Or the transgenic mice were fed with sarms J 147 powder cas: 1146963-51-0 in their chow at 200 ppm starting at 4 months of age. sarms J 147 powder estimated potential human clinical trial dosings: J 147 dosing estimates as relates to any potential future human clinical trials, based off the animal data available, correlate to be anticipated at 20-30mg q.d. or b.i.d. for such focused toward neurogenic-dependent/neuroregenerative/anti-neurodegenerative (Alzheimer’s Disease, et. al.) antidepressant, mood stabilizing, and anti-addiction treatments.

Dosage that would appear to be of benefit for less critical conditions and/or cognitive enhancement would appear to be at 5-15mg q.d. or b.i.d. Oral bioavailailability appears modest, but significant. Theoretical applications within sublingual hydroalcoholic-glycerin based tinctures may be significantly superior.

 



3

AASraw Biochemical Technology Co.,Ltd aas14@aasraw.com